FOXO4 and prostate carcinoma: Target genes of differentially methylated enhancers were notably enriched in developmental pathways, various gene sets of known transcription factor (TF) targets (ETS2 proto-oncogene, FOXO4 tumour suppressor), and in prostate cancer-associated pathways (Dataset EV14).